Inovio doses first participant of COVID-19 vaccine mid-stage trial

Inovio Pharmaceuticals Inc said on Monday it has dosed the first participant in a mid-stage clinical trial testing its COVID-19 vaccine candidate, INO-4800.

The Phase 2 portion of the Phase 2/3 study will enroll about 400 participants who are 18 years or older, to assess the vaccine's ability to produce immune response and to determine the dose for a later study, the company said.